Skip to content

Text Size: AAA

Press Releases

The information in these news pages is accurate or current only as of the date of the particular press release or posting. Amylin does not update press releases once they have been made public. Press releases may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

DATE TITLE

07/27/10

Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010

07/21/10

Amylin Pharmaceuticals Reports Second Quarter Financial Results

07/14/10

Amylin Pharmaceuticals to Webcast Second Quarter Results

06/26/10

Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010

06/26/10

Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R)

06/26/10

Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010

06/26/10

Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes

06/26/10

BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010

06/17/10

Amylin Pharmaceuticals to Present New Data and Insights From the Company's Diabetes Programs at ADA 2010

06/15/10

DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
Back to TopMore Press Releases